We have created a platform of proprietary, selective FASN inhibitors.
Our lead product candidate TVB-2640 is an oral, highly potent, selective and reversible, first-in-class inhibitor of FASN. TVB-2640 is rapidly absorbed in human with well-behaved pharmacokinetics.
Our early clinical development strategy provided proof of concept for target engagement and inhibition of de novo lipogenesis by TVB-2640 in relevant patient populations.
